NovoCure - NVCR Competitors

Globus Medical (NYSE:GMED) and NovoCure (NASDAQ:NVCR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.

Which has more volatility & risk, GMED or NVCR?

Globus Medical has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Does the media favor GMED or NVCR?

In the previous week, NovoCure had 1 more articles in the media than Globus Medical. MarketBeat recorded 5 mentions for NovoCure and 4 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.75 beat NovoCure's score of 0.18 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend GMED or NVCR?

Globus Medical currently has a consensus price target of $70.91, suggesting a potential upside of 33.44%. NovoCure has a consensus price target of $87.33, suggesting a potential upside of 52.76%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	1 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.09
NovoCure	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the MarketBeat Community favor GMED or NVCR?

Globus Medical received 74 more outperform votes than NovoCure when rated by MarketBeat users. Likewise, 68.86% of users gave Globus Medical an outperform vote while only 65.29% of users gave NovoCure an outperform vote.

Company	Underperform	Outperform
Globus Medical	Outperform Votes 533 68.86%	Underperform Votes 241 31.14%
NovoCure	Outperform Votes 459 65.29%	Underperform Votes 244 34.71%

Which has higher earnings & valuation, GMED or NVCR?

Globus Medical has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$759.12 million	7.02	$190.17 million	$1.86	28.57
NovoCure	$537.84 million	11.21	-$92.53 million	-$0.88	-64.97

Is GMED or NVCR more profitable?

Globus Medical has a net margin of 18.59% compared to NovoCure's net margin of -17.20%. Globus Medical's return on equity of 11.93% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.59%	11.93%	10.62%
NovoCure	-17.20%	-20.98%	-7.91%

Do insiders & institutionals have more ownership in GMED or NVCR?

74.2% of Globus Medical shares are owned by institutional investors. Comparatively, 78.4% of NovoCure shares are owned by institutional investors. 24.4% of Globus Medical shares are owned by company insiders. Comparatively, 6.2% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Globus Medical beats NovoCure on 13 of the 17 factors compared between the two stocks.